EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC0

Immune response kinetics to SARS-CoV-2 infection and COVID-19 vaccination among nursing home residents—Georgia, October 2020–July 2022

Zeshan A Chisty iD, Deana D Li, Melia Haile, Hollis Houston, Juliana DaSilva, Rahsaan Overton, Amy J Schuh, Jenn Haynie iD, Jacob Clemente, Alicia G Branch, Melissa M Arons, Clarisse A Tsang iD und 15 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0301367 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Zeshan A Chisty und 26 weiteren Autor:innen. Beteiligte Einrichtung: COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Understanding the immune response kinetics to SARS-CoV-2 infection and COVID-19 vaccination is important in nursing home (NH) residents, a high-risk population.

Methods

An observational longitudinal evaluation of 37 consenting vaccinated NH residents with/without SARS-CoV-2 infection from October 2020 to July 2022 was conducted to characterize the immune response to spike protein due to infection and/or mRNA COVID-19 vaccine. Antibodies (IgG) to SARS-CoV-2 full-length spike, nucleocapsid, and receptor binding domain protein antigens were measured, and surrogate virus neutralization capacity was assessed using Meso Scale Discovery immunoassays. The participant’s spike exposure status varied depending on the acquisition of infection or receipt of a vaccine dose. Longitudinal linear mixed effects modeling was used to describe trajectories based on the participant’s last infection or vaccination; the primary series mRNA COVID-19 vaccine was considered two spike exposures. Mean antibody titer values from participants who developed an infection post receipt of mRNA COVID-19 vaccine were compared with those who did not. In a subset of participants (n = 15), memory B cell (MBC) S-specific IgG (%S IgG) responses were assessed using an ELISPOT assay.

Results

The median age of the 37 participants at enrollment was 70.5 years; 30 (81%) had prior SARS-CoV-2 infection, and 76% received Pfizer-BioNTech and 24% Moderna homologous vaccines. After an observed augmented effect with each spike exposure, a decline in the immune response, including %S IgG MBCs, was observed over time; the percent decline decreased with increasing spike exposures. Participants who developed an infection at least two weeks post-receipt of a vaccine were observed to have lower humoral antibody levels than those who did not develop an infection post-receipt.

Conclusions

These findings suggest that understanding the durability of immune responses in this vulnerable NH population can help inform public health policy regarding the timing of booster vaccinations as new variants display immune escape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansAgedCOVID-19 VaccinesGeorgiaSARS-CoV-2VaccinationImmunityNursing HomesRNA, MessengerImmunoglobulin GAntibodies, Viral

Substanzen

COVID-19 VaccinesRNA, MessengerImmunoglobulin GAntibodies, Viral

Autor:innen und Institutionen

  • COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Goldbelt C6, LLC, Chesapeake, Virginia, United States of America.
  • A.G. Rhodes Wesley Woods Heath and Rehab, Atlanta, Georgia, United States of America.
  • Emory Healthcare, Atlanta, Georgia, United States of America.
  • Emory University School of Medicine, Atlanta, Georgia, United States of America.
  • Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

ORCID-Profile: Zeshan A Chisty, Jenn Haynie, Clarisse A Tsang, Hyungseok Oh, Allison C Brown

Zitieren

APA

Chisty, Z. A., Li, D. D., Haile, M., Houston, H., DaSilva, J., Overton, R., Schuh, A. J., Haynie, J., Clemente, J., Branch, A. G., Arons, M. M., Tsang, C. A., Pellegrini, G. J., Bugrysheva, J., Ilutsik, J., Mohelsky, R., Comer, P., Hundia, S. B., Oh, H., …, & Kutty, P. K. (2024). Immune response kinetics to SARS-CoV-2 infection and COVID-19 vaccination among nursing home residents—Georgia, October 2020–July 2022. PLOS ONE. https://doi.org/10.1371/journal.pone.0301367

Vancouver

Chisty ZA, Li DD, Haile M, Houston H, DaSilva J, Overton R, et al. Immune response kinetics to SARS-CoV-2 infection and COVID-19 vaccination among nursing home residents—Georgia, October 2020–July 2022. PLOS ONE. 2024. doi:10.1371/journal.pone.0301367

BibTeX
@article{Chisty2024,
  author = {Chisty, Zeshan A and Li, Deana D and Haile, Melia and Houston, Hollis and DaSilva, Juliana and Overton, Rahsaan and Schuh, Amy J and Haynie, Jenn and Clemente, Jacob and Branch, Alicia G and Arons, Melissa M and Tsang, Clarisse A and Pellegrini, Gerald J and Bugrysheva, Julia and Ilutsik, Justina and Mohelsky, Romy and Comer, Patricia and Hundia, Solomon B and Oh, Hyungseok and Stuckey, Matthew J and Bohannon, Caitlin D and Rasheed, Mohammed Ata Ur and Epperson, Monica and Thornburg, Natalie J and McDonald, L Clifford and Brown, Allison C and Kutty, Preeta K},
  title = {Immune response kinetics to SARS-CoV-2 infection and COVID-19 vaccination among nursing home residents—Georgia, October 2020–July 2022},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0301367}
}
Kostenlos starten →